Renal Cell Carcinoma Clinical Trials

48 studies are recruiting for renal cell carcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Drug Screening Using Novel IMD in Renal Cell Carcinoma

   This research is being done to study the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of 19 specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against metastatic renal cell carcinoma (RCC). The n…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Run by

   Oliver Jonas

   See if you can join NCT05700461 on ClinicalTrials.gov

2. Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

   The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Run by

   Diwakar Davar

   See if you can join NCT07223424 on ClinicalTrials.gov

3. Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus

   The primary objective of this study is to evaluate whether the combination of Pembrolizumab and Axitinib given in the neoadjuvant setting can change the Inferior Vena Cava Tumor Thrombus burden. A decrease in the size of the tumor thrombus can potentially lead to decrease in surgical complications,…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Colorado Cancer Center, Aurora, Colorado

   Locations

   3 in total

   Run by

   University of Colorado, Denver

   See if you can join NCT05969496 on ClinicalTrials.gov

4. A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

   This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study nea…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Colorado Cancer Center, Aurora, Colorado

   Locations

   5 in total

   Run by

   7 Hills Pharma, LLC

   See if you can join NCT06362369 on ClinicalTrials.gov

5. A Study of VET3-TGI in Patients With Solid Tumors

   VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or whe…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   USC/Norris Comprehensive Cancer Center, Los Angeles, California

   Locations

   7 in total

   Run by

   KaliVir Immunotherapeutics

   See if you can join NCT06444815 on ClinicalTrials.gov

6. Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma

   This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Sibley Memorial Hospital, Washington D.C., District of Columbia

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT06376669 on ClinicalTrials.gov

7. Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations

   Single arm, single site, open-label Phase II study of the effects of oral olaparib in participants with metastatic renal cell carcinoma that harbor an inactivating mutation in BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L who ha…

   Stage

   Phase 2

   Ages

   18 to 120

   Site

   Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT03786796 on ClinicalTrials.gov

8. Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

   The purpose of this study is to see whether the drug casdatifan is safe and effective either by itself or in combination with the drug zimberelimab in participants with resectable clear cell renal cell carcinoma (ccRCC). The names of the study drugs involved in this study are: * Casdatifan (a type …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   3 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT07397611 on ClinicalTrials.gov

9. Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

   This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1. Our study will ultimately facilitate the development of novel screening, prevention and treatment stra…

   Stage

   Not phased

   Ages

   Any age

   Site

   The Ohio State University Wexner Medical Center, Columbus, Ohio

   Run by

   Mohamed Abdel-Rahman

   See if you can join NCT04792463 on ClinicalTrials.gov

10. A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma

    The researchers are doing this study to find out whether it is practical (feasible) to give cemiplimab and fianlimab before a nephrectomy and whether it causes any delays with surgery in people with kidney cancer. The researchers will also look at whether cemiplimab and fianlimab given before a nep…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (Limited Protocol Activites), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06699602 on ClinicalTrials.gov

11. Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation

    This phase II trial studies how well contrast-enhanced ultrasound (CEUS) works for diagnosing patients with renal cell cancer (RCC) that has come back (recurrent) after an ablation. Diagnostic imaging, such as CEUS, may help find and monitor long term renal cell cancer recurrence following cryo or …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania

    Run by

    john eisenbrey

    See if you can join NCT05641935 on ClinicalTrials.gov

12. An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy

    The purpose of this study is to understand the metabolism of cancers involving the kidney, including renal cell carcinomas and urothelial cell carcinomas, and how kidney cancers use different types of fuel to support tumor growth. This study uses specially labeled nutrient tracers of compounds norm…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Texas Southwestern Medical Center, Dallas, Texas

    Run by

    University of Texas Southwestern Medical Center

    See if you can join NCT04623502 on ClinicalTrials.gov

13. A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

    This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalation, and a combination dose expansion. Approximately 80 patie…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Arizona Cancer Center, Tucson, Arizona

    Locations

    20 in total

    Run by

    HiberCell, Inc.

    See if you can join NCT06234605 on ClinicalTrials.gov

14. Retifanlimab and Ruxolitinib In Solid Malignancies

    The goal of this clinical trial is to learn what dose of ruxolitinib can be given safely together with retifanlimab in patients with metastatic renal cell carcinoma and non-small cell lung carcinoma. The main question it aims to answer is: What is the maximum dose of ruxolitinib that can be used sa…

    Stage

    Phase 1

    Ages

    Any age

    Site

    University of California, San Diego Moores Cancer Center, La Jolla, California

    Run by

    University of California, San Diego

    See if you can join NCT07219576 on ClinicalTrials.gov

15. Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma

    This Phase II trial will evaluate progression-free survival after Stereotactic Body Radiation Therapy to oligoprogressive (1-5) lesions in metastatic renal cell carcinoma patients on any immune checkpoint inhibitor-containing regimen with last dose of systemic therapy within 3 months prior to trial…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Yale University, New Haven, Connecticut

    Run by

    Yale University

    See if you can join NCT04974671 on ClinicalTrials.gov

16. [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma

    This is an exploratory study to assess [18F]PT2385 Positron Emission Tomography/Computed Tomography (PET/CT) in patients with renal cell carcinoma (RCC). This is an open-label, nontherapeutic trial. The main objective is to correlate hypoxia-inducible factor-2alpha (HIF2α) levels as determined by a…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UT Southwestern Medical Center, Dallas, Texas

    Run by

    Orhan Kemal Oz

    See if you can join NCT04989959 on ClinicalTrials.gov

17. Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)

    The goal of this Clinical Study is to understand the outcomes by informing therapy choice for adjuvant treatment in clear cell renal cell carcinoma by using molecular residual disease. The main question[s] it aims to answer are: * what is the progression free survival of a cohort of high risk resec…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT06005818 on ClinicalTrials.gov

18. Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)

    The goal of this clinical trial is to learn about the effects of a higher dose of ncabozantinib in patients with advanced renal cell carcinoma who have progressed on or after receiving cabozantinib treatment.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UT Southwestern Medical Center, Dallas, Texas

    Run by

    University of Texas Southwestern Medical Center

    See if you can join NCT05931393 on ClinicalTrials.gov

19. A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

    The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Banner MD Anderson Cancer Center, Gilbert, Arizona

    Locations

    10 in total

    Run by

    A2 Biotherapeutics Inc.

    See if you can join NCT06682793 on ClinicalTrials.gov

20. A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

    This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Beijing Cancer Hospital, Beijing,

    Locations

    38 in total

    Run by

    Xynomic Pharmaceuticals, Inc.

    See if you can join NCT03592472 on ClinicalTrials.gov

21. A Multicenter Cancer Biospecimen Collection Study

    This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent st…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Curebase, San Francisco, California

    Run by

    Cofactor Genomics, Inc.

    See if you can join NCT04510129 on ClinicalTrials.gov

22. Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

    This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab [Gazyva®] pre-treatment, by IV infusion, and in combination with pembrolizumab. A Phase 2 monotherapy arm is also planned;…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    HonorHealth Research Institute, Scottsdale, Arizona

    Locations

    6 in total

    Run by

    Simcha IL-18, Inc.

    See if you can join NCT04787042 on ClinicalTrials.gov

23. The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors

    The microbiome has the potential to serve as a robust biomarker of clinical response to immunotherapy. Additionally, microbial manipulation, through diet, exercise, prebiotics, probiotics, or microbially-derived metabolites, may prove to be beneficial in promoting anti-tumor immune responses. Howev…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Baptist Health Clinical Research, Elizabethtown, Kentucky

    Run by

    VastBiome

    See if you can join NCT05037825 on ClinicalTrials.gov